Dr. Reddys Laboratories has launched Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg a therapeutic equivalent generic version of Vytorin (Ezetimibe and Simvastatin) Tablets in the United States market, approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's is among the first companies to laun..
Dr. Reddy’s Laboratories is currently trading at Rs. 2619.00, up by 10.30 points or 0.39% from its previous closing of Rs. 2608.70 on the BSE. The scrip opened at Rs. 2616.00 and has touched a high and low of Rs. 2623.75 and Rs. 2615.95 respectively. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3689.00 on 20-Jul-201..
Reliance Industries (RIL) has commenced commercial production from its Coal Bed Methane (CBM) block SP (West)-CBM-2001/1 from March 24, 2017 and is currently supplying CBM for commissioning the Shahdol Phulpur Pipeline (SHPPL). The production from the company’s Sohagpur CBM fields will gradually ramp-up in the next 15-18 months making RIL among the..
Dr. Reddy’s Laboratories has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version of Prometrium (Progesterone) Capsules in the United States market, approved by the U.S. Food and Drug Administration (USFDA). The company’s Progesterone Capsules, 100 mg and 200 mg, are available in bottle count size of 100. Prom..
Dr Reddys Laboratories has submitted the Shareholding Pattern for the Period Ended March 31, 2017. The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Reddy's Laboratories has informed that a meeting of the Board of Directors of the Company will be held on Friday, May 12, 2017, to consider and approve the Audited Financial Results of the Company for the fina..
Dr. Reddys Laboratories is currently trading at Rs. 2686.00, up by 44.60 points or 1.69% from its previous closing of Rs. 2641.40 on the BSE. The scrip opened at Rs. 2718.00 and has touched a high and low of Rs. 2721.95 and Rs. 2683.30 respectively. So far 50420 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touc..
Dr. Reddy’s Laboratories’ API manufacturing plant at Srikakulam (SEZ) in state of Andhra Pradesh has completed the audit by the US Food and Drug Administration (USFDA) on April 14, 2017 with no observations. Besides, the company is recalling 1,728 bottles of Rivastigmine Tartrate capsules, used for treatment of dementia, due to cross-contamination ..
Dr. Reddy’s Laboratories is recalling 1,728 bottles of Rivastigmine Tartrate capsules, used for treatment of dementia, due to cross-contamination with other products from the US market. The company's US arm, Dr. Reddy’s Laboratories Inc is recalling Rivastigmine Tartrate capsules 1.5 mg in 60-count bottle manufactured by Dr. Reddy’s Laboratories in..
Please find enclosed a Press Release on 'Dr. Reddy's Laboratories announces the launch of Ezetimibe and Simvastatin Tablets in the U.S. Market'.
Please find enclosed a Press Release on 'Dr. Reddy's to release Q4 and Full Year FY17 results on May 12, 2017 Earnings call slated for May 12, 6.00 PM IST / 8.30 AM EDT.'
Please find enclosed a Press Release on 'Dr. Reddy's Laboratories announces the launch of Progesterone Capsules in the U.S. Market.'
Clarification on news item appeared on CNBC TV18 dated April 3, 2017 captioned ‘US FDA started Srikakulam inspection on March 27, 2017. No major observation from US FDA yet on Srikakulam plant.' This is with reference to your email dated April 3, 2017, seeking clarification on the above subject. ‘In this regard, please note that the..
The Exchange has sought clarification from Dr Reddys Laboratories Ltd on April 03, 2017, with reference to news flashed on CNBC TV18 dated April 03, 2017 quoting "USFDA started srikakulam inspection on march 27. No major observation from USFDA yet on srikakulam plant."The reply is awaited.
Dr. Reddy's and Integra LifeSciences enter into an agreement to market and distribute DuraGen Plus® and Suturable DuraGen® Dural Regeneration in India. Dr. Reddy's Laboratories Limited (BSE:500124, NSE:DRREDDY, NYSE:RDY) and Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technolog